Innate Pharma (IPHA) Stock Statistics & Valuation Metrics

Innate Pharma has a market cap or net worth of $130.56M. The enterprise value is $106.42M.

Innate Pharma has 93,768,590 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma’s return on equity (ROE) is 2.18 and return on invested capital (ROIC) is -134.69%.

The current PE Ratio of Innate Pharma is ―. Innate Pharma’s PEG ratio is 0.21.

In the last 12 months, Innate Pharma had revenue of 2.79M and earned -47.24M in profits. Earnings per share was -0.53.

In the last 12 months, operating cash flow was -54.56M and capital expenditures -143.05K, giving a free cash flow of -54.70M billion.

Innate Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma upcoming earnings date is Sep 10, 2026, Before Open (Confirmed).

Innate Pharma as a current ratio of 1.27, with Debt / Equity ratio of -104.00%

In the past 12 months, Innate Pharma has paid -5.96M in taxes.

Innate Pharma EV to EBITDA ratio is -2.92, with an EV/FCF ratio of -2.51.

Innate Pharma has $34.30M in cash and marketable securities with $22.56M in debt, giving a net cash position of $11.73M billion.

Gross margin is 100.00%, with operating margin of -1916.94%, and net profit margin of -1694.87%.

The average price target for Innate Pharma is $6.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy